返回 Agenda
How Can We Address AMR “Broken Business Model” to Activate Antibacterial R&D? Policy Needs, Potential Solutions and Examples
Session Chair(s)
Keiko Tone, MBA
VP EU Market Access and Policy
Shionogi, United Kingdom
Pull incentives for antibacterial R&D are needed imminently, as pipeline is drying out and companies continue exiting this area. Industry, clinicians, academia and authorities discuss the issues, potential solutions and examples of new incentives.
Learning Objective : • Recognise the AMR policy needs for pull incentives to stimulate antibacterial R&D • Contrast the different cost to achieve a cure for antibacterials and other curative therapies such as treatments for oncology and hepatitis C • Discuss different options for incentivising R&D and access to antibacterials • Share practical example/s implemented to improve antibacterial access
Speaker(s)
Cost of Cure – Analysis of Difference by Disease Area
Claudio Jommi, MSC
SDA Bocconi School of Management, Italy
Professor of Practice at SDA Bocconi
Antibiotic Challenges and Way Forward – Broken Business Model and HTA Approach
Lotte Steuten, PHD, MS
Office of Health Economics, United Kingdom
Vice President, Head of Consulting
Implementation of New Incentives for Antibiotics – Example from England
David Glover
NHS England and NHS Improvement, United Kingdom
General Manager